Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Plasmodium falciparum parasites resistant to the combination sulfadoxine-pyrimethamine are spreading in Africa, particularly in East Africa. This is a matter of concern because there are no other affordable drugs available. This article provides the evidence indicating that sulfadoxine-pyrimethamine resistance can be reversed in vitro and discusses how this information might be exploited to extend the therapeutic lifetime of sulfadoxine-pyrimethamine in vivo.

Original publication

DOI

10.1016/j.pt.2003.12.005

Type

Journal article

Journal

Trends Parasitol

Publication Date

03/2004

Volume

20

Pages

109 - 112

Keywords

Animals, Antimalarials, Drug Combinations, Drug Resistance, Drug Synergism, Drug Therapy, Combination, Folic Acid, Folic Acid Antagonists, Malaria, Falciparum, Plasmodium falciparum, Probenecid, Pyrimethamine, Sulfadoxine